LUND, Sweden, Nov. 6, 2020 /PRNewswire/ -- Immunovia invites to
a teleconference (in English) for investors, analysts and media on
Thursday, November 12, 2020 at
16:30 CET. Immunovia will publish the
company's interim report on November 12,
2020 at 16:00 CET.
Patrik Dahlen, CEO will present
Immunovia and comment on the interim report for the period January
- September 2020 followed by a
Q&A session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below and
provide the conference code Immunovia to the
operator:
Conference Call
Sweden: +46 (0) 8 50520424
United States: +1 212 999
6659
France: +33 (0) 1 7037 7166
Denmark: +45 3272 9273
Germany: +49 (0) 30 3001
90612
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 708
5073
Norway: +47 2 156
3318
Austria: +43 (0)
12530807
Switzerland: +41 (0) 22 592
7915
United Kingdom (Standard
International Access): +44 (0) 20 3003 2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia Webcast:
https://channel.royalcast.com/immunovia/#!/immunovia/20201112_1
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia's webpage under
Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january---september-2020-on-november-12--20,c3232456
The following files are available for download:
https://mb.cision.com/Main/13121/3232456/1331438.pdf
|
Release
|